Key Development

Sudeep Pharma Limited has received approval from the Gujarat Food and Drug Control Administration (FDA) for its new pharma greenfield manufacturing facility located at 179 Nandesari, Gujarat. The approval authorizes the Company to commence manufacturing operations at the site.

Facility Details

  • Location: 179 Nandesari, Gujarat
  • Type: Greenfield manufacturing facility
  • Annual installed capacity: 51,200 MT
  • Product focus: Pharmaceutical excipients, food and nutrition ingredients, and specialty mineral-based solutions

Capacity Allocation

  • 60% of capacity allocated to existing Pharma, Food & Nutrition portfolio
  • 40% of capacity allocated to newer product categories including phosphates, glycinates, gluconates, and citrates
  • Dedicated capacity for higher-value ingredients and new-age, high-value molecules such as bisglycinates

Commercial Timeline

Commercial supplies from this facility are expected to commence in H2 FY27 (second half of financial year 2026-27), following the completion of customer qualification processes and audits.

Strategic Significance

The approval confirms that the facility's manufacturing systems, quality controls, and compliance framework meet regulatory requirements. The facility will:

  • Strengthen manufacturing capabilities across Pharma, Food & Nutrition, and Specialty Ingredients
  • Serve growing demand from pharmaceutical, food and nutrition customers in domestic and international markets
  • Enable portfolio diversification and strengthen presence in regulated markets
  • Address capacity constraints for bisglycinates and other specialized ingredients from the existing mother plant

Management Commentary

Mr. Sujit Bhayani, Managing Director, stated: "The FDA approval marks an important milestone in our growth journey, enabling us to commence manufacturing operations and unlock significant additional capacity. It strengthens our ability to serve a wider customer base across pharmaceutical, food and nutrition segments in India and international markets. This investment will serve as an important growth driver as we progress into the next phase of our journey."

Investor Relations Contact

Strategic Growth Advisors Pvt. Ltd. (CIN: U74140MH2010PTC204285)

  • Mr. Shrikant Sangani / Ms. Shaily Patwa
  • Mobile: 9619595686 / 9819494608